Heterologous Booster Profiles for Recipeints of CoronaVac Inactivated Primary Vaccine: A Scoping Review
Abstract
The administration of booster vaccines has been implemented in a number of countries. Unfortunately, there are limited studies of the immune response after booster to recipient with CoronaVac inactivated primary vaccine. This scoping review aims to determine heterologous booster profiles for recipients of the CoronaVac inactivated primary vaccine. This study obtained data from PubMed, Cochrane Library, Medrxiv, Google Scholar and Grey literature. The inclusion criteria were Sars-Cov-2 article, heterologous boosters and CoronaVac vaccine published from 2020 to 2022, written in English, and in a form of an original research articles, project reports, articles with RCT research designs, cohorts and articles with human research subjects. The keywords were Sars-cov-2, COVID-19, heterologous boosters and CoronaVac. Profiles assessed were heterologous vaccine types, immune responses, intervals between the booster administration and the primary vaccine, and heterologous booster doses. The number of articles that met the inclusion criteria was 19 articles. Types of vaccines that could be used as heterologous boosters for recipients of CoronaVac inactivated primary vaccine were BNT162b2, AZD1222, mRNA-1273, Ad26.COV2-S. The administration of heterologous booster vaccines for recipients of the CoronaVac inactivated primary vaccine was able to increase antibody levels against of the Sars-Cov-2 variants of Mild, Beta, Gamma, Delta and Omicron. The doses of booster vaccines (Ad26.COV2-S, BNT162b2, AZD1222, mRNA-1273 (Moderna) and CoronaVac) for the CoronaVac recipients respectively were 0.5 mL, 0.3 mL, 0.5mL, 100 µg and 0.5 mL. In conclusion, the heterologous boosters for the CoronaVac recipients could enhance immune responses against the Sars Cov 2.
Keywords
Full Text:
PDFReferences
Worldometers.info. COVID-19 Coronavirus Pandemic [Internet]. Worldometers.info. [cited 2022 Feb 9]. Available from: https://www.worldometers.info/coronavirus/#countries
Covid19.go.id. Data Sebaran Perkembangan Covid-19 [Internet]. Covid19.go.id. 2022 [cited 2022 Feb 9]. Available from: https://covid19.go.id/
Muhamad S. Pandemi Covid-19 Sebagai Persoalan Serius Banyak Negara di Dunia. Info Singk. 2021;8(13).
Dong Y, Mo X HY. Epidemiological Characteristics of 2143 Pediatric Patients with 2019 Coronavirus Disease in China. American Academy of Pediatrics. 2020.
Shereen MA, Khan S, Kazmi A, Bashir N SR. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. J Adv Res. 2020;24:91–8.
Li Q, Guan X WP. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;
Krammer F. SARS-CoV-2 Vaccines in Development: Review. Nature. 2020;586.
Who.int. Draft Lanscape of Covid-19 Candidate Vaccines [Internet]. who.int. 2022 [cited 2022 Feb 9]. Available from: https://www.who.int/ publications/m/item/draftlandscape-of-covid-19-candidatevaccines
Indonesia KKR. Survei Penerimaan Vaksin Covid-19 di Indonesia. Jakarta Indonesia; 2020.
Chiu NC, Chi H, Tu YK, Huang YN, Tai YL, Weng SL, et al. To mix or not to mix? A rapid systematic review of heterologous prime–boost covid-19 vaccination. Expert Rev Vaccines [Internet]. 2021;20(10):1211–20. Available from: https://doi.org/10.1080/14760584.2021.1971522
Ho TC, Chen YMA, Chan HP, Chang CC, Chuang KP, Lee CH, et al. The effects of heterologous immunization with prime‐boost covid‐19 vaccination against sars‐cov‐2. Vaccines. 2021;9(10):1–14.
Costa Clemens SA, Weckx L, Clemens R, Almeida Mendes AV, Ramos Souza A, Silveira MB V, et al. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Lancet. 2022;399:521–9.
Mok CKP, Cheng SM., Chen C, Yiu K, Chan TO, Lai KC, et al. A RCT of a third dose CoronaVac or BNT162b2 vaccine in adults with two doses of CoronaVac [Internet]. Hong Kong; 2021. Available from: https://doi.org/10.1101/2021.11.02.21265843
Çağlayan D, Süner AF, Şiyve N, Güzel I, Irmak Ç, Işik E, et al. An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey. J Med Virol. 2022;(December 2021):1–10.
Khong KW, Liu D, Leung KY, Lu L, Lam HY, Chen L, et al. Antibody Response of Combination of BNT162b2 and CoronaVac Platforms of COVID-19 Vaccines against Omicron Variant. Vaccines. 2022;10(2):1–10.
Leung NHL, Cheng SMS, Martin-Sanchez M, Au NYM, Ng YY, Luk LLH, et al. BNT162b2 vaccine boosts neutralizing antibodies to ancestral SARS-CoV-2 & Omicron variant in adults who previously received two doses of inactivated vaccine [Internet]. medRxiv. Hongkong; 2022. Available from: http://medrxiv.org/content/early/2022/01/21/2022.01.20.22269586.abstract
Nantanee R, Aikphaibul P, Jaru-Ampornpan P, Sodsai P, Himananto O, Theerawit T, et al. Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac [Internet]. Bangkok; 2021. Available from: https://doi.org/10.1101/2021.12.12.21267695
Zuo F, Abolhassani H, Du L, Piralla A, Bertoglio F, de Campos-Mata L, et al. Heterologous immunization with inactivated vaccine followed by mRNA booster elicits strong humoral and cellular immune responses against the SARS-CoV-2 Omicron variant [Internet]. medRxiv. Huddinge, Sweden; 2022. Available from: http://medrxiv.org/content/early/2022/01/06/2022.01.04.22268755.abstract
Jara A, Undurraga EA, Zubizarreta JR, Gonzalez C, Pizarro A, Acevedo J, et al. Effectiveness of Homologous and Heterologous Booster Shots for an Inactivated SARS-CoV-2 Vaccine: A Large-Scale Observational Study [Internet]. SSRN Electronic Journal. Chile; 2022. Available from: https://ssrn.com/abstract=4005130
Li J, Hou L, Guo X, Jin P, Wu S, Zhu J, et al. Heterologous prime-boost immunization with CoronaVac and Convidecia Jingxin [Internet]. Beijing, China; 2021. Available from: https://doi.org/10.1101/2021.09.03.21263062
Yorsaeng R, Suntronwong N, Phowatthanasathian H, Assawakosri S, Kanokudom S, Thongmee T, et al. Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults. Vaccine [Internet]. 2022;40(3):524–30. Available from: https://doi.org/10.1016/j.vaccine.2021.11.083
Can F, Kuloglu ZE, El R, Esken G, Tok Y, Zeynep T, et al. Immunogenicity of BNT162b2 and CoronaVac boosters in fully vaccinated individuals with CoronaVac against SARS-CoV-2 : A Longitudinal Study [Internet]. Istambul, Turkey; 2022. Available from: https://authorea.com/users/455648/articles/552940-immunogenicity-%0Aof-bnt162b2-and-coronavac-boosters-in-fully-vaccinated-individuals-with-coronavac-%0Aagainst-sars-cov-2-a-longitudinal-study
Huang Q, Zeng J, Lang Q, Gao F, Liu D, Tian S, et al. Impact of various vaccine boosters on neutralization against Omicron following prime vaccinations with inactivated or adenovirus-vectored vaccine [Internet]. Beijing, China; 2022. Available from: https://doi.org/10.1101/2022.01.25.476850
Patamatamkul S, Thammawat S, Buranrat B. Induction of robust neutralizing antibodies against the COVID-19 Delta variant with ChAdOx1 nCoV-19 or BNT162b2 as a booster following a primary vaccination series with CoronaVac [Internet]. medRxiv. Thailand; 2021. Available from: http://medrxiv.org/content/early/2021/09/28/2021.09.25.21264099.abstract
Assawakosri S, Kanokudom S, Suntronwong N, Auphimai C, Nilyanimit P, Vichaiwattana P, et al. Neutralizing Activities against the Omicron Variant after a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination [Internet]. Thailand; 2022. Available from: https://doi.org/10.1101/2022.01.28.22269986
Pérez-Then E, Lucas C, Monteiro VS, Miric M, Brache V, Cochon L, et al. Immunogenicity of heterologous BNT162b2 booster in fully vaccinated individuals with CoronaVac against SARS-CoV-2 variants Delta and Omicron: the Dominican Republic Experience [Internet]. medRxiv. Dominican Republic; 2021. Available from: https://www.medrxiv.org/content/10.1101/2021.12.27.21268459v1%0Ahttps://www.medrxiv.org/content/10.1101/2021.12.27.21268459v1.abstract
Kanokudom S, Assawakosri S, Suntronwong N, Auphimai C, Nilyanimit P, Vichaiwattana P, et al. Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine. Vaccines. 2022;10(1):1–13.
Vargas L, Valdivieso N, Tempio F, Simon V, Sauma D, Valenzuela L, et al. Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 S antibodies [Internet]. medRxiv. Chile; 2022. Available from: https://www.medrxiv.org/content/10.1101/2022.01.14.22269289v1%0Ahttps://www.medrxiv.org/content/10.1101/2022.01.14.22269289v1.abstract
Sinto R, Utomo D, Suwarti S, Nelwan EJ, Surendra H, Natasha C, et al. Serum anti-Spike antibody titers before and after heterologous booster with mRNA-1273 SARS-CoV-2 vaccine following two doses of inactivated whole-virus CoronaVac vaccine [Internet]. medRxiv. Jakarta Indonesia; 2021. Available from: https://www.medrxiv.org/content/10.1101/2021.12.24.21268360v1%0Ahttps://www.medrxiv.org/content/10.1101/2021.12.24.21268360v1.abstract
Angkasekwinai N, Niyomnaitham S, Sewatanon J, Phumiamorn S, Sukapirom K, Senawong S, et al. The immunogenicity against variants of concern and reactogenicity of four COVID-19 booster vaccinations following CoronaVac or ChAdOx1 nCoV-19 primary series [Internet]. medRxiv. 2022. Available from: https://www.medrxiv.org/content/10.1101/2021.11.29.21266947v2%0Ahttps://www.medrxiv.org/content/10.1101/2021.11.29.21266947v2.abstract
DOI: https://doi.org/10.15416/ijcp.2023.12.1.68
Refbacks
- There are currently no refbacks.
Indonesian Journal of Clinical Pharmacy is indexed by
